NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
National Institutes of Health (NIH)
Maximum budget of $1,515,000 in direct costs per year
Project duration of up to 3 years
To support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for HLBS disorders in adults and children.
Investigators conducting clinical trials
Patients with heart, lung, blood, and sleep disorders
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments.
Specific qualifications include having the necessary skills, knowledge, and resources to carry out the proposed research.
U.S. organizations can apply; non-domestic (non-U.S.) entities are not eligible to apply.
Non-domestic components of U.S. organizations are eligible.
Projects must be phase I clinical trials for HLBS disorders.
Trials can be single or multi-site.
Application budgets should not exceed $1,515,000 in direct costs per year.
Cost sharing is not required.
Applications are due by 5:00 PM local time of the applicant organization.
The earliest submission date is January 3, 2025, and the expiration date is January 8, 2027.
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications.
Applications must include a detailed listing of clinical trial research experience and a project management plan.
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Applications will undergo peer review and be evaluated for scientific and technical merit.
Funding decisions will consider scientific merit, availability of funds, and relevance to program priorities.
Applicants must be ready to initiate the clinical trial within the first quarter of the project period.
Applications that do not comply with submission instructions may be delayed or not accepted.
Investigators are encouraged to consult with NHLBI staff prior to submission.
The grant emphasizes milestone-driven funding, which may provide a structured approach to project management.
Meeting defined milestones is crucial for continued funding.
Ensure compliance with all application instructions to avoid delays.
Engage with NHLBI staff early in the application process.
Highlight the significance and innovation of the proposed clinical trial in the application.